EP0063434A1 - Ein Penicillin-Derivat enthaltende pharmazeutische Zusammensetzung zur Behandlung von bakteriellen Ansteckungen - Google Patents

Ein Penicillin-Derivat enthaltende pharmazeutische Zusammensetzung zur Behandlung von bakteriellen Ansteckungen Download PDF

Info

Publication number
EP0063434A1
EP0063434A1 EP82301715A EP82301715A EP0063434A1 EP 0063434 A1 EP0063434 A1 EP 0063434A1 EP 82301715 A EP82301715 A EP 82301715A EP 82301715 A EP82301715 A EP 82301715A EP 0063434 A1 EP0063434 A1 EP 0063434A1
Authority
EP
European Patent Office
Prior art keywords
compound
treatment
formula
dosage
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP82301715A
Other languages
English (en)
French (fr)
Other versions
EP0063434B1 (de
Inventor
Robert Sutherland
Brian Slocombe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beecham Group PLC
Original Assignee
Beecham Group PLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beecham Group PLC filed Critical Beecham Group PLC
Publication of EP0063434A1 publication Critical patent/EP0063434A1/de
Application granted granted Critical
Publication of EP0063434B1 publication Critical patent/EP0063434B1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Definitions

  • This invention relates to a method of treatment employing compounds having pharmaceutical activity and to the unit dosage composition used therein. More specifically this invention relates to the treatment of bacterial infection with a penicillin derivative and to the unit dosage composition used therein.
  • U.K. Patents Numbers 1538051 and 1538052 disclose inter alia the compounds of formula (I): wherein R is hydrogen, a pharmaceutically acceptable salting ion or a pharmaceutically acceptable ester-forming radical, and
  • U.K. Patents Numbers 1538051 and 1538052 further disclose pharmaceutical compositions comprising a compound of formula (I) above together with a pharmaceutical carrier or excipient.
  • the present invention provides a method of treatment of bacterial infections in humans which comprises administering to a patient one or two unit dosages per day of a compound of formula (I).
  • the administration comprises a single unit dosage per day.
  • compositions may be formulated for administration by any route, although parenteral administration is preferred.
  • the compositions may be in the form of tablets, capsules, powders, granules, lozenges, or liquid preparations, such as oral or sterile parenteral solutions or suspensions.
  • Tablets and capsules for oral administration may be in unit dose presentation form, and may contain conventional excipients such as binding agents, for example syrup, acacia, gelatin, sorbitol, tragacanth, or polyvinyl-pyrollidone; fillers, for example lactose, sugar, maize-starch, calcium phosphate, sorbitol or glycine; tabletting lubricants, for example magnesium stearate, talc, polyethylene glycol, or silica; disintegrants, for example potato starch; or acceptable wetting agents such as sodium lauryl sulphate.
  • the tablets may be coated according to methods well known in normal pharmaceutical practice.
  • Oral liquid preparations may be in the form of, for example, aqueous or oil suspensions, solutions, emulsions, syrups, or elixirs, or may be presented as dry product for reconstitution with water or other suitable vehicle before use.
  • Such liquid preparations may contain conventional additives such as suspending agents, for example sorbitol, syrup, methyl cellulose, glucose syrup, gelatin, hydroxyethylcellulose, carboxymethyl cellulose, aluminium stearate gel or hydrogenated edible fats, emulsifying agents, for example lecithin, sorbitan monooleate, or acacia; nonaqueous vehicles (which may include edible oils), for example almond oil, fractionated coconut oil, oily esters such as glycerine, porpylene glycol, or ethyl alcohol; preservatives, for example methyl or propyl p-hydroxybenzoate or sorbic acid, and if desired convention flavouring or colouring agents.
  • suspending agents for example sorbi
  • Suppositories will contain conventional suppository bases, e.g. cocoa, butter or other glyceride.
  • fluid unit dosage forms are prepared utilizing the compound and a sterile vehicle, water being preferred.
  • the compound depending on the vehicle and concentration used, can be either suspended or dissolved in the vehicle.
  • the compound can be dissolved in water for injection and filter sterilized before filling into a suitable vial or ampoule and sealing.
  • adjuvants such as a local anesthetic, preservative and buffering agents can be dissolved in the vehicle.
  • the composition can be frozen after filling into the vial and the water removed under vacuum. The dry lyophilized powder is then sealed in the vial and an accompanying vial of water for injection is supplied to reconstitute the liquid prior to use.
  • Parenteral suspensions are prepared in substantially the same manner except that the compound is suspended in the vehicle instead of being dissolved and sterilization cannot be accomplished by filtration.
  • the compound can be sterilized by exposure to ethylene oxide before suspending in the sterile vehicle.
  • a surfactant or wetting agent is included in the composition to facilitate uniform distribution of the compound.
  • compositions may contain from 0.1% to 99% by weight, preferably from 10-60% by weight, of the active material, depending on the method of administration.
  • the unexpected properties of the compounds (I) enable a therapeutically effective level of compound to be present in the blood stream over a period of 24 hrs.
  • the dosage as employed for adult human treatment will suitably range from 500 to 3000 mg per unit dose, preferably the dosage will be in the range from 750 to 1250 mg per unit dose, with a unit dose of 1000 mg being a convenient standard dosage unit.
  • the dosage will depend on the route of administration of the composition; however for administration by intravenous or intramuscular injection a unit dose of 1000 mg is particularly preferred.
  • the present invention further provides a pharmaceutical container comprising unit dosages of a compound of formula (I), said container being associated with an indication to administer one or two unit dosages per day.
  • the dosage units administered according to the method of the invention do not require any sustained release formulations to maintain the high and prolonged serum concentrations of compound (I).
  • One preferred embodiment of the present invention provides a method of treatment of bacterial infections in humans which comprises administering to a patient one or two unit doses per day of a compound of formula (II): wherein R 3 and R 4 may be the same or different and each represents hydrogen or a pharmaceutically acceptable salting ion.
  • R 3 and R 4 both represent sodium.
  • the compound of formula (II) may suitably be administered by the parenteral route, preferably as a solution in sterile water or sterile isotonic saline B.P.
  • Example 6p-(2-carboxy-2-thien-3-yl acetamido)-6a-methoxy penicillanic acid, disodium salt is referred to by the reference number BRL 17421.
  • BRL 17421 was dosed by intramuscular injection (i.m.) to 25 healthy volunteers, including three females at the 1,000 mg dose level, and by intravenous (i.v.) injection to 18 healthy volunteers, including three females at the 1,000 mg dose level. All the volunteers participating in the reported studies were aged between 18 and 45 years and had passed a comprehensive medical examination during the previous 12 months and a complete haematological and clinical chemistry check prior to each study. Volunteers were fasted for up to 10 h and provided blood and urine samples immediately prior to dosing. Each volunteer was standardised with regard to food and fluid intake for the duration of the study. Volunteers with known penicillin hypersensitivities or had received medication up to seven days before the commencement of the study were excluded.
  • the doses were prepared from vials of sterile freeze-dried BRL 17421, containing either 250 mg or 500 mg as pure free acid (pfa), which was reconstituted in 2 ml volumes of sterile water B.P. for i.m. doses, or in lO ml volumes or isotonic saline B.P. for i.v. doses.
  • the 1,000 mg dose was reconstituted from two vials containing 500 mg BRL 17421 (pfa) and dissolved in 2 ml volumes of sterile water B.P. for i.m. administration and 20 ml sterile isotonic saline B.P. for i.v. dosage.
  • the 2 ml i.m. dose was injected deep into the outer quadrant of the gluteus-maximus and the i.v. administrations were given as a fast bolus injection of either 10 ml or 20 ml over 30 sec into the antecubital vein.
  • BRL 17421 Mean serum concentrations of BRL 17421 following i.m. dosage are shown in Fig. 1, and after bolus i.v. injections in Fig 2.
  • a summary of some pharmacokinetic parameters derived after parenteral administration of BRL 17421 is given in Table 1.
  • BRL 17421 gave high and prolonged serum levels with a terminal serum half-life which ranged between 5.0 and 5.4 h. The peak serum concentrations were reached approximately 2 h after dosing.
  • a single i.m. injection of 500 mg gave a mean peak serum concentration of 48 ⁇ g/ml and levels in excess of 20 ⁇ g/ml were maintained for 8 h.
  • Administration of a single 1,000 mg dose gave a mean peak serum concentration of 70 ⁇ g/ml approximately 2 h after dosing, with levels in excess of 18 ⁇ g/ml for 12 h.
  • a single 1,000 mg dose gave serum concentrations in excess of 25 ⁇ g/ml for up to 6 h and a level of approx. 12 ⁇ g/ml 12 h after dosing. No antibiotic was detected in the serum 24 h after administration of the 1,000 mg dose by the i.v. route.
  • the urinary recoveries of unmetabolised BRL 17421 after both routes of administration was high, ranging from 72-82% after i.v. and 82-92% after i.m. administration.
  • the concentrations of BRL 17421 (as pfa) in serum or urine were determined by microbiological assay using P. aeruginosa NCTC 10701 as the assay organism.
  • the limit of detection of BRL 17421 in human serum was approximately 3 ⁇ g/ml.
  • the sensitivity of the microbiological assay was generally increased two-fold by the incorporation of calcium chloride in the nutrient agar medium at a final concentration of 10 mM, allowing detection of BRL 17421 (pfa) at approximately 1.5 ⁇ g/ml in the presence of human serum.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP82301715A 1981-04-15 1982-04-01 Ein Penicillin-Derivat enthaltende pharmazeutische Zusammensetzung zur Behandlung von bakteriellen Ansteckungen Expired - Lifetime EP0063434B1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB8111939 1981-04-15
GB8111939 1981-04-15

Publications (2)

Publication Number Publication Date
EP0063434A1 true EP0063434A1 (de) 1982-10-27
EP0063434B1 EP0063434B1 (de) 1991-10-30

Family

ID=10521187

Family Applications (1)

Application Number Title Priority Date Filing Date
EP82301715A Expired - Lifetime EP0063434B1 (de) 1981-04-15 1982-04-01 Ein Penicillin-Derivat enthaltende pharmazeutische Zusammensetzung zur Behandlung von bakteriellen Ansteckungen

Country Status (9)

Country Link
US (1) US4481210A (de)
EP (1) EP0063434B1 (de)
JP (1) JPS57179116A (de)
AU (1) AU548476B2 (de)
DE (1) DE3280370D1 (de)
IE (1) IE57156B1 (de)
NZ (1) NZ200177A (de)
PT (1) PT74737B (de)
ZA (1) ZA822567B (de)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1538052A (en) * 1975-01-17 1979-01-10 Beecham Group Ltd 6-methoxy-6-(alpha-carboxyethienylaceamido)-penicillins

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1538051A (en) * 1975-01-17 1979-01-10 Beecham Group Ltd 6-methoxy-6-(alpha-carboxyacetamido)-penicillins

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1538052A (en) * 1975-01-17 1979-01-10 Beecham Group Ltd 6-methoxy-6-(alpha-carboxyethienylaceamido)-penicillins

Also Published As

Publication number Publication date
PT74737A (en) 1982-05-01
AU8255882A (en) 1982-10-21
AU548476B2 (en) 1985-12-12
IE57156B1 (en) 1992-05-20
PT74737B (en) 1983-11-09
ZA822567B (en) 1983-02-23
US4481210A (en) 1984-11-06
DE3280370D1 (de) 1991-12-05
NZ200177A (en) 1985-09-13
EP0063434B1 (de) 1991-10-30
JPS57179116A (en) 1982-11-04
IE820882L (en) 1982-10-15

Similar Documents

Publication Publication Date Title
US5008242A (en) Treatment of inflammation using 1-antichymotrypsin
JPS6191131A (ja) 医薬品の吸着防止方法および組成物
IE60290B1 (en) "Stable pharmaceutical preparation containing granulocyte colony stimulating factor and process for producing the same"
EP1045695A1 (de) Verwendung von 9-deoxy-2',9-alpha-methano-3-oxa-4,5,6-trinor-3,7-(1',3'-interphenylen)-13,14-dihydroprostaglandin-f1 zur behandlung von peripheren vaskulären krankheiten
EP0590514B1 (de) Zusammensetzung und Verfahren zur Blutkonservierung
US4322411A (en) Anti-inflammatory nucleosides
US4836957A (en) Stabilized active forms of vitamin D3
US4312866A (en) Use of rifamycin SV and its related salts in the treatment of rheumatoid arthritis, and related formulations suited for the purpose
CA1336003C (en) Pentamidine salts useful in the treatment and prophylaxis of pneumocystis carinii pneumonia
Herrell Further observations on the clinical use of penicillin
CN113493415B (zh) 一种青藤碱衍生物代谢产物及其制备方法、药物组合物和用途
IE63156B1 (en) Dry substances and stable suspensions
Mitchard et al. Mecillinam serum levels following intravenous injection: a comparison with pivmecillinam
EP0448029B1 (de) Neue pharmazeutische Verwendungen von Forskolin-Derivaten
EP0038567B1 (de) Deazapurin-Nukleosid, es enthaltende Zusammensetzungen und seine therapeutische Verwendung
US4481210A (en) Method of treatment
US4892876A (en) Method for inhibiting HIV and an pharmaceutical composition therefor
JPS62153224A (ja) プラスミノゲン製剤
JPH05504550A (ja) 免疫抑制剤として有用なピリミジン生合成インヒビター
JP2812683B2 (ja) 持続性を有するモルヒネ直腸投与製剤
Poochikian et al. Morphine acetate
Rahbari Pruritic Papules of Pregnancy
EP0238207A1 (de) Bakterientötende Gemische
JP2639729B2 (ja) 放射線による副作用軽減剤
EP0335627A2 (de) Verwendung eines Thrombroxanantagonisten gegen die Nierentoxizität, induziert von Cyclosporin-A

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Designated state(s): BE CH DE FR GB IT NL SE

17P Request for examination filed

Effective date: 19821217

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): BE CH DE FR GB IT LI NL SE

REF Corresponds to:

Ref document number: 3280370

Country of ref document: DE

Date of ref document: 19911205

ET Fr: translation filed
ITF It: translation for a ep patent filed
PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed
EAL Se: european patent in force in sweden

Ref document number: 82301715.7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 19950322

Year of fee payment: 14

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Effective date: 19960402

EUG Se: european patent has lapsed

Ref document number: 82301715.7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20010313

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20010319

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20010405

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20010430

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 20010516

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20010627

Year of fee payment: 20

BE20 Be: patent expired

Free format text: 20020401 *BEECHAM GROUP P.L.C.

REG Reference to a national code

Ref country code: GB

Ref legal event code: IF02

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20020331

Ref country code: GB

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20020331

Ref country code: CH

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20020331

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20020401

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

NLV7 Nl: ceased due to reaching the maximum lifetime of a patent

Effective date: 20020401

NLV7 Nl: ceased due to reaching the maximum lifetime of a patent

Effective date: 20020401